Red Arrow Therapeutics, K.K.
Development of pH-sensitive polymers as an inovative platform for protein delivery
As of January, 2025
| City | Year of Establishment | Founder |
|---|---|---|
| Tokyo | 2021 | Takuya Miyazaki Horacio Cabral Rika Tajima |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| University of Tokyo Edge Capital Partners | Seed Extension | - |
- Contact Information: 03-6820-0861
- rika@redarrowtx.com
- Website:Red Arrow Therapeutics, K.K.
Program name
Deep-Tech Startups Support Program
Research theme
Development of pH-sensitive polymers as an inovative platform for protein delivery
Business Plan
We are developing pH-sensitive polymers as protein delivery systems. Our polymers can stably encapsulate therapeutic proteins at physiological pH while they can release active proteins at pathological pH. Since we have obtained early in vivo PoC, we are working on R&D activities to synthesize building blocks including polymers, proteins and their conjugates. Thus, by showing both therapeutic data and manufacturing data to pharmaceuticals as our potential customers, we are aiming to collaborate with them to translate our technology into business practice.
Research Outline
Since our systems are comprising polymers, proteins and their conjugates, we would like to conduct R&D activities to synthesize all these building blocks as follows:
- [1] Development of synthesis method for polymers aiming to larger-scale manufacturing
- [2] Development of synthesis method for proteins aiming to larger-scale manufacturing
- [3] Development of synthesis method for conjugates aiming to larger-scale manufacturing
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| STS | Healthcare | 2024～2025FY | JPY 356 million |
International collaborative technology demonstration
| Countries/Regions | Collaborative activity outline |
|---|---|
| Europe |
|
Last Updated : May 22, 2025